# First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer

> **NCT01853813** · PHASE2 · COMPLETED · sponsor: **Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente** · enrollment: 85 (actual)

## Conditions studied

- Colorectal Cancer Stage II

## Interventions

- **DRUG:** Bevacizumab and FOLFIRI

## Key facts

- **NCT ID:** NCT01853813
- **Lead sponsor:** Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2015-05
- **Final completion:** 2015-07
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2015-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01853813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01853813, "First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01853813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*